Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream

Vito Di Lernia, C. Ricci, G. Albertini

Research output: Contribution to journalArticle

Abstract

Imiquimod, the first member of a new class of immune response modifiers, is approved for the treatment of external genital and perianal warts. Recently, many clinical trials highlighted the potential of imiquimod as a treatment for other viral infections and cutaneous neoplasms. We report two cases of facial keratoacanthomas (KA) treated with topical 5% imiquimod cream. Patients were successfully cleared of KAs after treatment for 8 weeks. No recurrence occurred after a 1 -year follow-up. Despite the fact that KAs are characterized by the potential for spontaneous regression, it is possible that a faster activation of CD4+ lymphocytes, via interferon release and cytokine secretion takes place after imiquimod application leading to KA regression.

Original languageEnglish
Pages (from-to)626-629
Number of pages4
JournalJournal of the European Academy of Dermatology and Venereology
Volume18
Issue number5
DOIs
Publication statusPublished - Sep 2004

Keywords

  • Imiquimod
  • Interferon
  • Keratoacanthoma
  • Tumour

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream'. Together they form a unique fingerprint.

  • Cite this